SwePub
Sök i LIBRIS databas

  Utökad sökning

WFRF:(Berg Daniela)
 

Sökning: WFRF:(Berg Daniela) > (2020-2022) > Safinamide in the t...

  • Stocchi, FabrizioIRCCS San Raffaele Pisana (författare)

Safinamide in the treatment pathway of Parkinson’s Disease : a European Delphi Consensus

  • Artikel/kapitelEngelska2022

Förlag, utgivningsår, omfång ...

  • 2022-02-21
  • Springer Science and Business Media LLC,2022

Nummerbeteckningar

  • LIBRIS-ID:oai:lup.lub.lu.se:2660ddbe-a668-4725-b979-0b62e18572f9
  • https://lup.lub.lu.se/record/2660ddbe-a668-4725-b979-0b62e18572f9URI
  • https://doi.org/10.1038/s41531-022-00277-zDOI

Kompletterande språkuppgifter

  • Språk:engelska
  • Sammanfattning på:engelska

Ingår i deldatabas

Klassifikation

  • Ämneskategori:art swepub-publicationtype
  • Ämneskategori:ref swepub-contenttype

Anmärkningar

  • Safinamide is a highly selective, reversible MAO B-inhibitor recently marketed in European and North American countries. To better define clinical indications regarding motor and non-motor symptoms, targeted population and safety of this compound, ten movement disorders specialists, experts in their field, convened and developed a panel of statements on: the role of glutamate in Parkinson’s disease, introduction to fluctuations, efficacy of safinamide on motor symptoms, motor complications and non-motor symptoms, quality of life, safety of safinamide and target population for use. Strong consensus was reached for all the statements on the efficacy of safinamide on motor symptoms, motor fluctuations, quality of life and safety. Among non-motor symptoms, a positive consensus was reached for the symptoms sleep/fatigue, mood, and pain while there was a lack of consensus for the statements regarding the efficacy of safinamide in improving cognition, urinary and sexual functions. The statement on orthostatic hypotension obtained a negative consensus. The consistent and large agreement reached in this Delphi panel perfectly reflects the perception of efficacy, safety and tolerability of safinamide as evident from pivotal trials and clinical practice and shows how these findings may guide movement disorders specialists in their clinical therapeutic approach. The impact of non-motor symptoms in PD is considerable, and management remains an unmet need. In this context, the ability of safinamide to impact some non-motor symptoms may represent the most promising and distinctive feature of this compound and deserves further investigations.

Ämnesord och genrebeteckningar

Biuppslag (personer, institutioner, konferenser, titlar ...)

  • Antonini, AngeloUniversity of Padova,Center for Rare Neurological Diseases (ERN-RND) (författare)
  • Berg, DanielaUniversity of Kiel,University of Tübingen (författare)
  • Bergmans, BrunoGhent University Hospital (författare)
  • Jost, WolfgangParkinson’s Disease Clinic Ortenau (författare)
  • Katzenschlager, ReginaKarl Landsteiner Institute for Neuroimmunological and Neurodegenerative Disorders (författare)
  • Kulisevsky, JaimeHospital de Sant Pau,Autonomous University of Barcelona,CIBER Enfermedades Neurodegenerativas (CIBERNED) (författare)
  • Odin, PerLund University,Lunds universitet,Neurologi, Lund,Sektion IV,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Restorative Parkinson Unit,Forskargrupper vid Lunds universitet,Neurology, Lund,Section IV,Department of Clinical Sciences, Lund,Faculty of Medicine,Lund University Research Groups(Swepub:lu)med-poi (författare)
  • Valldeoriola, FrancescHospital Clínic of Barcelona,University of Barcelona,Institutd' Investigacions Biomèdiques August Pi iSunyer (IDIBAPS),CIBER Enfermedades Neurodegenerativas (CIBERNED) (författare)
  • Ray Chaudhuri, K.King's College London (författare)
  • IRCCS San Raffaele PisanaUniversity of Padova (creator_code:org_t)

Sammanhörande titlar

  • Ingår i:npj Parkinson's Disease: Springer Science and Business Media LLC82373-8057

Internetlänk

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy